Reference-based pricing

CMAJ. 2000 Jan 11;162(1):14; author reply 14,18.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / economics
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Canada
  • Cost Control
  • Cost-Benefit Analysis
  • Drug Costs*
  • Drug Utilization Review*
  • Humans
  • Hypertension / drug therapy
  • Reproducibility of Results
  • Therapeutic Equivalency

Substances

  • Angiotensin-Converting Enzyme Inhibitors